Top Markets
#1 Zora Zora +33.04%
#2 AI XOVIA AI XOVIA +26.43%
#3 0G 0G +20.34%
#4 Full Moon Full Moon +18.72%
#5 Helium Helium +16.76%
#6 Notcoin Notcoin +15.68%
#7 Axelar Axelar +12.89%
#8 Wrapped NXM Wrapped NXM +12.33%
#9 rsERG rsERG +12.19%
#10 Yield Basis Yield Basis +10.82%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rank in Stocks #12737
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Share Price
$22.26
Last synced: 2024-03-22
Market Cap
$553.40M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Graphite Bio, Inc. (GRPH)

Category

Healthcare
Earnings for Graphite Bio, Inc. (GRPH)
Earnings in 2026 TTM: 0
According to Graphite Bio, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Graphite Bio, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH